If you have been reading about receptor agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
==== Netherlands ==== In the Netherlands, the Opium Law classifies all barbiturates as List II drugs, with the exception of secobarbital, which is on List I. There is a small group of List II drugs for which physicians have to write the prescriptions according to the same, tougher guidelines as those for List I drugs (writing the prescription in full in letters, listing the patients name, and have to contain the name and initials, address, city and telephone number of the licensed prescriber issuing the prescriptions, as well as the name and initials, address and city of the person the prescription is issued to). Among that group of drugs are the barbiturates amobarbital, butalbital, cyclobarbital, and pentobarbital.
=== Biosynthesis of the aromatic amino acids === The shikimate pathway, named after shikimic acid as important intermediate, is a seven-step metabolic route used by bacteria, fungi, algae, parasites, and plants for the biosynthesis of aromatic amino acids (phenylalanine, tyrosine, and tryptophan). This pathway is not found in animals; therefore, phenylalanine and tryptophan are essential nutrients and must be obtained from the animal's diet. Tyrosine is not essential, as it can be synthesized from phenylalanine, except for individuals unable to hydroxylate phenylalanine to tyrosine.
== Detection == The first line of defense in preventing chronic Somogyi rebound is additional blood glucose testing. Continuous glucose monitoring is the preferred method to detect and prevent the Somogyi rebound, but this technology is far from universally used. Alternatively, testing blood sugar more often, 8 to 10 times daily with a traditional blood glucose meter, facilitates detecting the low blood sugar level before such a rebound occurs. Testing occasionally during the middle of the night is also important, particularly when high waking blood sugars are found, to determine if more insulin is needed to prevent hyperglycemia or if less insulin is needed to prevent such a rebound. Sometimes a person with diabetes will experience the Somogyi rebound when awake and notice symptoms of the initial low blood sugar or symptoms of the rebound. Waking with a night sweat (perhaps combined with a rapid heart rate) is a symptom of the adrenaline and rebound. Unfortunately, the evidence shows that patients with type 1 diabetes do not normally wake during nocturnal hypoglycemic episodes. While reviewing log data of blood glucose after the fact, signs of Somogyi rebound should be suspected when blood glucose numbers seem higher after the insulin dosage has been raised, particularly in the morning. One simple way to determine if nocturnal hypoglycemia may be causing morning hyperglycemia is to have the patient have a high protein snack with a small amount of carbohydrates at bedtime. This will help keep the blood sugar up overnight and prevent the Somogyi effect.
== See also == Aneutronic fusion Cold fusion Fusion power Neutrino astronomy Nuclear fusion Proton–proton chain, as found in stars like the Sun Stellar nucleosynthesis, the whole topic Triple-alpha process, how 12C is produced from lighter nuclei
== Interactions == HLA-G has been shown to interact with CD8A. When in its soluble form, HLA-G interacts with Ig-like transcript 2 (ILT2), a leukocyte receptor. When it is membrane bound, it interacts with Ig-like transcript 4 (ILT4). Soluble HLA-G can bind to KIR2DL4, which is often found on the surface of natural killer cells. The identity of the peptide presented by HLA-G is unrelated to the binding of HLA with KIR2DL4, ILT2, or ILT4. Because HLA-G interacts with receptors using a variety of its domains, multiple antibodies are necessary to inhibit all of its functions. Both ILT2 and ILT4 cause negative intracellular signaling. In monocytes, binding to either ILT2 or ILT4 receptors cause the inhibition of monocyte/macrophage mediated toxicity. In dendritic cells, binding to both receptors can prevent dendritic cells from maturing and prevent the activation of T cells. Additionally, HLA-G may interact with ILT4 receptors on the surface of neutrophils to inhibit phagocytosis. In natural killer cells, HLA-G binds with the ILT2 receptor to inhibit the secretion of IFN-γ, a cytokine that can activate macrophages and stimulate natural killer cells and neutrophils. HLA-G binds to ILT2 on B cells to cause the inhibition of B cell proliferation, differentiation, and the secretion of antibodies. It binds to ILT2 on T cells to downregulate T cell chemokine expression. The cytokine expression of T cells mimics that of TH2 cells. HLA-G causes apoptosis in CD8+ T cells. All together these effects serve to decrease the inflammatory response of the immune system.
Sources: en.wikipedia.org
DBNPA dust may cause mechanical (abrasive) irritation to the skin, eyes and respiratory system and is severely irritating to the eyes and may cause permanent corneal damage. Skin contact may cause an allergic skin reaction. Pre-existing skin disorders may even be aggravated by over-exposure to this product. Regarding long-term health effects, DBNPA contains material that may cause target organ damage, based on animal data. Repeated or prolonged inhalation of DBPNA dust can lead to chronic respiratory problems. Once sensitized, an allergic skin reaction may occur when subsequently exposed to very low levels of DBNPA.
==== Sexuality ==== Hitchens was a supporter of gay rights. He opposed sodomy laws and supported same-sex marriage. He argued that the legalization of same-sex marriage was the "socialization of homosexuality" and "demonstrates the spread of conservatism" among the gay community. Hitchens was a genital integrity activist, strongly criticizing the tradition of both male circumcision and female genital mutilation. In accordance with his antitheism, Hitchens described the tolerance of metzitzah b'peh (a Jewish tradition of sucking blood from the penis after the removal of the male foreskin) as "another disgusting religious practice".
Holick helped develop the first clinical assays for 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, determined how vitamin D3 is made in the skin from sun exposure, and established how season, time of day, skin pigmentation, sunscreen use, and latitude influenced this vital cutaneous process. He established that the skin was not only the organ responsible for making vitamin D3 but was also a target tissue for its active form, 1,25-dihydroxyvitamin D3. He determined the extremely inhibitory effects of 1,25-dihydroxyvitamin D3 on keratinocyte proliferation and the promoting effects on differentiation, and translated these seminal observations by demonstrating that the topical application of 1,25-dihydroxyvitamin D3 and several of its analogs were effective for the treatment of psoriasis. He demonstrated that macrophages and prostate cells have the enzymatic machinery to produce 1,25-dihydroxyvitamin D3, and established that the extrarenal production of 1,25-dihydroxyvitamin D3 may play a crucial role not only in cancer prevention but also in regulating the immune system. He developed a vitamin D absorption test and demonstrated that vitamin D was bioavailable in orange juice, leading to fortification of juice products in the United States. He also used the test to demonstrate the major cause of vitamin D deficiency in obesity is sequestration of vitamin D in the fat. He helped perform dose escalation studies establishing how much vitamin D is required to maintain blood levels of 25-hydroxyvitamin D in the sufficient range for adults.
== Safety == In vivo dermal sensitization studies according to OECD 429 confirmed HBTU is a moderate skin sensitizer, showing a response at 0.9 wt% in the Local Lymph Node Assay (LLNA) placing it in Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Dermal Sensitization Category 1A. Thermal hazard analysis by differential scanning calorimetry (DSC) shows HBTU is potentially explosive.
=== Children === A review of loperamide in children under twelve years of age found that serious adverse events occurred only in children under three years of age. The study reported that the use of loperamide should be contraindicated in children who are under three years of age, systemically ill, malnourished, moderately dehydrated, or have bloody diarrhea. In 1990, all formulations of loperamide for children were banned in Pakistan. Formulations for children aged less than twelve years of age are only available via prescription in the UK.
Sources: en.wikipedia.org
Peripherally acting μ-opioid receptor antagonists (PAMORAs) are a class of chemical compounds that are used to reverse adverse effects caused by opioids interacting with receptors outside the central nervous system (CNS), mainly those located in the gastrointestinal tract. PAMORAs are designed to specifically inhibit certain opioid receptors in the gastrointestinal tract and with limited ability to cross the blood–brain barrier. Therefore, PAMORAs do not affect the analgesic effects of opioids within the central nervous system.
Less common but occasional symptoms include erythrocytosis, leukocytosis, and proteinuria. The physical changes of hypersomatotropism are a result of anabolic effects of growth hormone and IGF-1; these have a gradual onset and progress slowly. The overgrowth of soft tissue and bone changes cause weight gain, broadening of the skull, prognathia inferior, and an enlarged tongue. Thickening of the oropharyngeal tissue may lead to respiratory distress and stridor. Degenerative anthropathy is caused by proliferation of chondrocytes and changes to the joint geometry. Heart murmur occurs in most feline cases, further diagnostics may reveal cardiomegaly and other heart abnormalities. Congestive heart failure can occur during later stages of the disease. A 1990 study reported 50% of cats diagnosed with hypersomatotropism had developed renal failure within 8–36 months of initial examination; however, another study from 2007 found a 12% incidence of azotaemia. Renal failure is a very common disease in elderly cats and it is controversial as to whether or not feline hypersomatotropism affects the development of renal failure. In dogs the symptoms of diabetes mellitus commonly overshadows acromegalic symptoms.
wrapped up the two-and-a-half-month Battle of Okinawa (which cost the lives of 260,000 people, including 150,000 civilians), it was faced with the prospect of invading the Japanese home islands in an operation codenamed Operation Downfall. Based on the U.S. casualties from the preceding island-hopping campaigns, American commanders estimated that between 50,000 and 500,000 U.S. troops would die and at least 600,000–1,000,000 others would be injured while invading the Japanese home islands. The U.S. manufacture of 500,000 Purple Hearts from the anticipated high level of casualties during the U.S. invasion of Japan gave a demonstration of how deadly and costly it would be. President Harry S. Truman realized he could not afford such a high casualty rate, especially since over 400,000 American combatants had already died fighting in both the European and the Pacific theaters of the war. On July 26, 1945, the United States, the United Kingdom, and the Republic of China issued a Potsdam Declaration that called for the unconditional surrender of Japan. It stated that if Japan did not surrender, it would face "prompt and utter destruction". The Japanese government ignored this ultimatum, sending a message that they were not going to surrender. In response to the rejection, President Truman authorized the dropping of the atomic bombs. At the time of its use, there were only two atomic bombs available, and despite the fact that more were in production back in mainland U.S., the third bomb wouldn't be available for combat until September.
=== Pioneers === Walter Lee Gaines noted the activity of the pituitary in the lactation of cows in 1915. He also noted that anaesthesia could block lactation and response to the suckling reflex. Ernst and Berta Scharrer, of LMU Munich the Albert Einstein College of Medicine are credited as co-founders the field of neuroendocrinology with their initial observations and proposals in 1945 concerning neuropeptides. Geoffrey Harris is considered by many to be the "father" of neuroendocrinology. Harris, the Dr. Lee's Professor of Anatomy at Oxford University, is credited with showing that the anterior pituitary gland of mammals is regulated by hormones secreted by hypothalamic neurons into the hypothalamohypophysial portal circulation. By contrast, the hormones of the posterior pituitary gland are secreted into the systemic circulation directly from the nerve endings of hypothalamic neurons. This seminal work was done in collaboration with Dora Jacobsohn of Lund University. The first of these factors to be identified are thyrotropin-releasing hormone (TRH) and gonadotropin-releasing hormone (GnRH). TRH is a small peptide that stimulates the secretion of thyroid-stimulating hormone; GnRH (also called luteinizing hormone-releasing hormone) stimulates the secretion of luteinizing hormone and follicle-stimulating hormone. Roger Guillemin, a medical student of Faculté de Médecine of Lyon, and Andrew W. Schally of Tulane University isolated these factors from the hypothalamus of sheep and pigs, and then identified their structures.
=== Degradation of DNA during bisulfite treatment === A major challenge in bisulfite sequencing is the degradation of DNA that takes place concurrently with the conversion. The conditions necessary for complete conversion, such as long incubation times, elevated temperature, and high bisulfite concentration, can lead to the degradation of about 90% of the incubated DNA. Given that the starting amount of DNA is often limited, such extensive degradation can be problematic. The degradation occurs as depurinations resulting in random strand breaks. Therefore, the longer the desired PCR amplicon, the more limited the number of intact template molecules will likely be. This could lead to the failure of the PCR amplification, or the loss of quantitatively accurate information on methylation levels resulting from the limited sampling of template molecules. Thus, it is important to assess the amount of DNA degradation resulting from the reaction conditions employed, and consider how this will affect the desired amplicon. Techniques can also be used to minimize DNA degradation, such as cycling the incubation temperature. In 2020, New England Biolabs developed NEBNext Enzymatic Methyl-seq, an alternative enzymatic approach to minimize DNA damage. Instead of bisulfite, APOBEC is used to convert C into U. Distinction between C, 5mC, and 5hmC is granted by the further modifications that "protect" the modified bases from APOBEC.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
The lyophilized powder is dissolved in a suitable solvent, often sterile water or a buffered diluent, with gentle mixing rather than vigorous shaking. Foaming and shear should be avoided because they can promote aggregation. The resulting solution is then stored cold and protected from light.